Compare Enveric Biosciences Inc (ENVB) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Invesco S&P 500 Momentum ETF trades at $144.83. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SPMO | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $17.40 | $161.66 |
52-Week Low | $1.28 | $107.84 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
SPMO trades at $145.12, down 5.06% today amid neutral technical signals. The ETF maintains bullish moving averages but faces resistance near $150. Recent news highlights strong momentum performance with 7.5% gains in June 2026 (ETF Trends, 2026-07-01), though concentrated tech exposure introduces volatility. A $0.25 dividend is scheduled for June 2026.
Outlook remains constructive given AI-driven momentum tailwinds, but high concentration in tech sectors poses risks during market rotations. Analyst sentiment is mixed with neutral ratings outweighing buys. Key support sits at $143, with upside potential if momentum resumes above $152 resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
